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Abstract
Background: Intercellular adhesion molecule-1 (ICAM-1) is a cytoadhesion molecule implicated in the pathogenesis
of Plasmodium falciparum malaria. Elevated levels of soluble ICAM-1 (sICAM-1) have previously been reported with
increased malaria disease severity. However, studies have not yet examined both sICAM-1 concentrations and
monocyte ICAM-1 expression in the same cohort of patients. To better understand the relationship of soluble and
cellular ICAM-1 measurements in malaria, both monocyte ICAM-1 expression and sICAM-1 concentration were
measured in children with P. falciparum infection exhibiting a spectrum of clinical severity.
Methods: Samples were analysed from 160 children, aged 0.5 to 10.8 years, with documented P. falciparum
malaria in Kampala, Uganda. The patients belonged to one of three pre-study defined groups: uncomplicated
malaria (UM), severe non-fatal malaria (SM-s), and fatal malaria (SM-f). Subset analysis was done on those with
cerebral malaria (CM) or severe malaria anaemia (SMA). Monocyte ICAM-1 was measured by flow cytometry. sICAM-
1 was measured by enzyme immunoassay.
Results: Both sICAM-1 and monocyte cell-surface ICAM-1 followed a log-normal distribution. Median sICAM-1
concentrations increased with greater severity-of-illness: 279 ng/mL (UM), 462 ng/mL (SM-s), and 586 ng/mL (SM-f),
p < 0.0001. sICAM-1 levels were not statistically different among children with CM compared to SMA. Monocyte
ICAM-1 expression was significantly higher in cases of UM compared with SM-s or SM-f (p < 0.001) and was higher
among the subset of patients with CM compared with SMA, p < 0.0014. The combination of sICAM-1 and cellular
ICAM-1 identified distinct categories of patients (UM with low sICAM-1 and higher monocyte ICAM-1, CM with
both sICAM-1 and monocyte ICAM-1 high, and SMA with sICAM-1 high but monocyte ICAM-1 low).
Conclusion: In this cohort of children with P. falciparum malaria, sICAM-1 levels were associated with severity-of-
illness. Patients with UM had higher monocyte ICAM-1 expression consistent with a role for monocyte ICAM-1 in
immune clearance during non-severe malaria. Among the subsets of patients with either SMA or CM, monocyte
ICAM-1 levels were higher in CM, consistent with the role of ICAM-1 as a marker of cytoadhesion. Categories of
disease in pediatric malaria may exhibit specific combinations of soluble and cellular ICAM-1 expression.
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Intercellular adhesion molecule-1 (ICAM-1) is an
important cell adhesion molecule involved in inflamma-
tion and immunity. It is the principal ligand for leuko-
cyte function antigen-1 (LFA1) and directs localization
of leukocytes to areas of inflammation. ICAM-1 is
expressed on several tissues including endothelial cells,
monocytes, and lymphocytes. A soluble form of ICAM-
1 circulates in plasma. Soluble ICAM-1 is released from
cell-surface ICAM-1 by proteolytic cleavage in response
to inflammatory cytokines or endothelial damage. The
plasma half-life of circulating soluble ICAM-1 is not
known [1]. ICAM-1 is one of several cell adhesion mole-
cules important in Plasmodium falciparum malaria. Red
blood cells, infected with P. falciparum, express a para-
site-derived protein (Plasmodium falciparum erythrocyte
membrane protein-1, PfEMP-1) associated with knob-
like projections on the erythrocyte surface. Specific
protein domains of PfEMP-1 bind to different target
molecules of the infected host including blood group A
and B antigens, platelet glycoprotein IV (CD36), chon-
droitin sulfate, complement receptor-1, and ICAM-1.
ICAM-1 expression can have both beneficial and dele-
terious consequences to the infected host. Monocyte
ICAM-1 participates in the immune response to P. falci-
parum infection. ICAM-1 surface expression was shown
to be required for the interferon-g response of Natural
Killer cells to malaria-infected red cells [2]. Early pro-
duction of interferon-g has been shown to be protective
against malaria infection in both human studies [3,4]
and animal models [5]. In contrast, direct adhesion of
parasitized erythrocytes to ICAM-1 on cerebral endothe-
lial cells or co-localization of monocytes to areas of ery-
throcyte and platelet adhesion on cerebral endothelial
cells may contribute to cerebral malaria [6-8].
Evidence for the role of cell-surface ICAM-1 expres-
sion in cerebral malaria comes from histologic studies
[9]. Examination of brain tissue from patients who died
with cerebral malaria has demonstrated adhesion of
parasitized red cells, platelets, and leukocytes to brain
endothelium in association with increased endothelial
expression of ICAM-1 [6-8,10-12]. When dermal micro-
vasculature, rather than cerebral microvasculature was
examined, Turner et al observed that endothelial
ICAM-1 staining did not correlate with the severity of
malaria [13]. Thus, it is possible that expression of
ICAM-1 on dermal endothelial cells may not reflect
ICAM-1 expression on cerebral vasculature.
Laboratory studies also support a role for adhesion of
parasitized erythrocytes to ICAM-1 in malaria pathogen-
esis. Newbold et al found that in-vitro binding of parasi-
tized red cells to ICAM-1 was more common among
patients with cerebral malaria compared with controls
[14]. Tripathi et al demonstrated in-vitro that exposure
of human brain microvascular endothelial cell cultures
to either parasitized red cells or the supernatant of cul-
tured parasitized red cells resulted in increased expres-
sion of ICAM-1 on brain microvascular endothelial
cells, and suggested that ICAM-1 expression was driven
by P. falciparum proteins rather than host cytokines
[15]. Favre et al infected wild type and ICAM-1 knock
out mice with Plasmodium berghei and found that
despite similar levels of parasitaemia, wild type mice had
decreased survival, greater accumulation of macrophages
in brain venules and greater sequestration of parasitized
red cells in alveolar capillaries [16].
S o l u b l ep l a s m al e v e l so fI C A M - 1h a v eb e e nm e a -
sured in several studies of P. falciparum malaria. Initial
small studies identified increased levels of soluble
ICAM-1 in patients with severe malaria [17-21]. In a
larger case-control study conducted in the Gambia,
McGuire et al measured soluble ICAM-1 levels in 157
children with cerebral malaria, 89 with acute non-cere-
bral malaria, and 156 non-malarial controls [22]. Solu-
ble ICAM-1 levels were significantly higher (p < 0.001)
among those with malaria (735 ng/mL) compared with
controls (440 ng/mL), but did not discriminate those
with cerebral malaria. sICAM levels also correlated
with disease severity in the large study reported by
Turner et al [13]. More recently, Tchinda et al
reported plasma levels of soluble ICAM-1, soluble vas-
cular adhesion molecule-1, soluble endothelial cell leu-
kocyte adhesion molecule and TNF in children with
malaria in Cameroon. Among 114 children with severe
malaria, 55 children with uncomplicated malaria, and
43 non-malaria controls, soluble ICAM-1 levels were
significantly higher among those with severe disease
compared with either uncomplicated malaria or con-
trols. However, among those with severe malaria syn-
dromes, soluble ICAM-1 levels did not distinguish
cerebral malaria or severe malaria anaemia from other
malaria syndromes [23]. Taken together, the published
literature suggests that plasma ICAM-1 concentrations
are higher in patients with more severe disease, but
that levels cannot be used to distinguish children with
cerebral malaria.
Few clinical studies have examined ICAM-1 expression
on circulating monocytes among subjects with malaria.
Using flow cytometry, Jenkins et al examined monocyte
ICAM-1 expression among 117 children with severe
malaria and 239 with uncomplicated malaria [24]. Among
those with both severe and non-severe malaria, they
observed higher monocyte ICAM-1 expression at onset of
disease compared with convalescence. Monocyte ICAM-1
fluorescence was not different among those with cerebral
malaria versus those without cerebral malaria.
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face and soluble ICAM-1 among patients with severe
malaria syndromes, both peripheral blood monocyte
ICAM-1 expression and plasma soluble ICAM-1 con-
centrations were measured in a cohort of children with
acute P. falciparum infection in Kampala, Uganda. To
better understand both potentially beneficial and detri-
mental effects of ICAM-1 in malaria, soluble and cellular
ICAM-1 measurements were obtained at presentation of
illness among children with different categories of disease
severity including those with uncomplicated malaria,
severe malaria anaemia, and cerebral malaria.
Methods
Patients were selected for testing from those enrolled in
a larger observational case-control clinical study (enroll-
ment dates Oct 2007-Oct 2009) of children aged 6
months to 12 years with P. falciparum malaria treated
at Mulago Hospital in Kampala, Uganda. Prior to any
testing, patients were categorized into three groups:
uncomplicated malaria under treatment as outpatients
(UM), severe malaria survivors treated as inpatients
(SM-s), and fatal severe malaria treated as inpatients
(SM-f). In addition, patients were sub-categorized
according to WHO classifications of malaria syndromes
as either cerebral malaria (CM) or severe malaria anae-
mia (SMA). Patient samples from the above 3 categories
were selected from a larger study sample archive based
on availability of an adequate volume of previously
unthawed plasma. All patients had confirmed P. falci-
parum infection based on independent review of anon-
ymized and clinically blinded peripheral blood smears
by two experts at a university malaria confirmatory
laboratory (Makerere-UCSF Molecular Laboratory, Dr
Samuel Nsobya, Director). The number of parasitized
red cells was determined relative to leukocyte counts.
No threshold level of parasitaemia was required and
assessment of quantitative parasitaemia by independent
reviewers agreed within < 2%. The median concentra-
tion of parasitized red cells was 39,200/μL (range 64/μL-
2,033,920/μL). Peripheral blood samples were obtained
from each patient on one occasion at the time of pre-
sentation to hospital for care. Citrated plasma was sepa-
rated from whole blood by centrifugation, transferred to
screw-cap cryovials, and promptly frozen at -20°C
shortly after phlebotomy for later testing of soluble
ICAM-1 concentration. At the same phlebotomy, a per-
ipheral whole blood sample collected in EDTA was
tested for ICAM-1 expression on monocytes by flow
cytometry (see below). Patients were treated in the
Acute Care Unit of Mulago Hospital (a university teach-
ing hospital setting) by Study Clinicians skilled in the
management of paediatric malaria. Anti-malarial
treatment was administered according to Ugandan
national guidelines [25]. Parents of enrolled children
gave written informed consent to participate in the
study and to test stored samples. The study was
approved by the Research Ethics Board of the University
of Toronto, Makerere University College of Health
Sciences, and the Uganda National Council for Science
and Technology.
Soluble ICAM-1 levels
Soluble ICAM-1 levels were measured using a human
ELISA (DuoSet™) from R&D Systems (Minneapolis,
MN). Patient plasma samples were diluted 1:1,000 with
phosphate buffered saline (PBS) supplemented with 1%
w/v bovine serum albumin (BSA). The ELISA was per-
formed in duplicate according to the manufacturer’s
instructions with the following changes: the assay was
performed in a volume of 50 μL/well; the recommended
top standard was quadrupled to give a 10-point calibra-
tion curve; plasma samples were incubated overnight at
4°C prior to washing; and the final reactions were devel-
oped using Extravidin™ (Sigma-Aldrich, St Louis, MO)
diluted 1:1000 in PBS with 1% BSA using a 45 min
incubation followed by addition of 4-nitrophenyl phos-
phate substrate (Sigma-Aldrich). Optical density read-
ings were acquired at 405 nm, and background (570
nm) was subtracted. For any given quantity (ng) of solu-
ble ICAM-1 in circulating blood, anemic individuals will
distribute that amount over a larger volume of plasma
compared with non-anemic individuals, resulting in a
lower measured plasma concentration. To correct for
the effects of anaemia, the measured plasma concentra-
tion of ICAM-1 was converted to the concentration
expected in whole blood, as follows:
Blood ICAM   ng mL blood plasma ICAM   ng ml plasma −= −× 11 1 (/ ) (/ ) ( − − Hct)
The values for blood ICAM-1 and plasma ICAM-1 are
listed in Additional file 1.
Monocyte ICAM-1 expression
ICAM-1 expression on monocytes was measured by
flow cytometry using a FACSCalibur™ (BD Biosciences;
San Jose, CA) with CellQuest™ (BD Biosciences, version
3.3) acquisition software and Flowjo™ (Tree Star, Ash-
land, OR) for analysis. Instrument setup and calibration
were performed daily with CaliBRITE™ beads according
to the manufacturer’s recommendations. Peripheral
blood, collected in EDTA, was tested within 48 hours of
collection. Previous work demonstrated that monocyte
ICAM-1 cell-surface levels were stable for 72 hours after
sample collection and were unaffected by the platelet
concentration in the sample [26]. Prior to beginning the
study, serial testing of samples stored as anticoagulated
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local temperatures demonstrated no statistical difference
between monocyte ICAM-1 measurements at day 0 (day
of phlebotomy) and day 3 of storage. During the study,
61% of patients were tested on the same day as phlebot-
omy or the next day, 21% on day 2, and 14% on day 3.
Thus > 95% of samples were tested within three days of
collection. There was furthermore no difference in
monocyte ICAM-1 expression distributions as a function
of the days of storage before cytometry testing (p =
0.245, ANOVA). Whole blood (100 μL) was incubated
for 15 minutes at room temperature with the following
monoclonal antibodies obtained from BD Biosciences:
anti-CD61-FITC (clone RUU-PL7F12); anti-CD54-APC
(clone HA58); and anti-CD14-PerCP (clone MF-P9).
Following incubation, the cell suspension was lysed,
washed, fixed and acquired within 24 hours. Gating
strategy was based on forward scatter vs side scatter vs
CD14 and CD14 vs CD61. Monocyte-platelet aggre-
gates, identified as events double-positive for both
CD14 and CD61, were eliminated from the final analy-
sis. CD54 expression on the resulting monocyte sing-
lets (CD14+ CD61-) was displayed as a histogram of at
least 4,000 CD14 positive events and the geometric
mean fluorescence intensity (MFI) channel recorded
for each sample.
Data analysis
Cumulative probability plots were used to characterize
the distribution of plasma soluble ICAM-1, whole blood
sICAM, and monocyte MFI. Comparison between multi-
ple groups was done by the Kruskal-Wallis test.
Comparison between two groups was done using the
Wilcoxon sum test. Correlations were tested for best fit
using an automated curve fitting programme [27].
Results
Patient samples were collected between October 2007
and October 2009. Patients selected for ICAM-1 analysis
were deliberately selected to represent three categories
of severity-of-illness: uncomplicated malaria treated as
an outpatient (UM); malaria survivors with severe
malaria anaemia or cerebral malaria treated as in-
patients (SM-s); and fatal malaria cases (SM-f). Clinical
characteristics of the patients are shown in Table 1. All
patients had confirmed P. falciparum infection.
Soluble and cellular ICAM-1, and severity of disease
Soluble plasma and whole blood ICAM-1 concentrations
followed a log-normal distribution. Soluble ICAM-1
concentrations progressively and significantly increased
with greater severity-of-illness. The median (inter-quar-
tile ranges) of soluble whole blood ICAM-1 concentra-
tions measured at presentation were: 279 ng/mL (206-
337) among UM patients; 462 ng/mL (360-542) among
SM-s patients; and 586 ng/mL (488-743) among SM-f
patients, p < 0.0001, Kruskal-Wallis test. See Figure 1.
Comparison of plasma ICAM-1 concentrations, rather
than whole blood ICAM-1 concentrations, gave similar
results: 421 ng/mL (320-472) among UM patients; 528
ng/mL (445-653) among SM-s patients; and 718 ng/mL
(647-895) among SM-f patients, p < 0.0001, Kruskal-
Wallis. The concentration of parasitized red cells did
not correlate with levels of sICAM-1.
Table 1 Clinical characteristics of the patients
All patients
n = 160
Uncomplicated
malaria
out-patients (UM),
n=5 3
Severe malaria
survivors
(SM-s)
n=8 0
Fatal malaria (SM-
f),*
n=2 7
Age (years) median (IQR) 2.2 (1.2 - 4.4) 4.4 (2.2 - 8) 1.6 (1 - 3.1) 1.9 (1.2-3.4)
Sex (female:male) 79:81 24:29 37:43 18:9
# of days ill prior to presentation median (IQR) 3 (3-4) 3 (2-4) 3 (3-4) 4 (2-6.5)
Haemoglobin (g/dL) median (IQR) 6.3 (4.2-9.6) 10.1 (9.4 - 11.3) 4.4 (3.4 - 5.6) 5.9 (4.6 - 8.5)
WBC/μL
median (IQR)
10,200 (6,800 - 14,300) 7,500 (5,200 - 9,000) 12,150 (9,375 - 16,000) 13,000 (8,500 -
25,125)
Monocytes/μL
median (IQR)
66 (39 - 114) 48 (33 - 63) 94 (50 - 137) 83 (51 - 125)
Parasitized red cells/μL
median (IQR)
39,600 (11,405-150,830) 37,680 (18,140-115,000) 37,010 (7,500-151,095) 118,920 (24,000-
271,350)
# with cerebral malaria 39 0 24 15
# with severe malaria anaemia 54 0 47 7
# with both cerebral malaria and severe malaria
anaemia
11 0 9 2
Patients with cerebral malaria or severe malaria anaemia are a subset of those with fatal or severe disease.
* Three patients with fatal malaria did not meet criteria for cerebral malaria or severe malarial anaemia.
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Page 4 of 10Figure 1 Blood levels of soluble ICAM-1 with increasing severity of malaria. Soluble ICAM-1 concentrations were significantly different
among the three groups, p < 0.0001 (Kruskal-Wallis). Levels among fatal cases were significantly higher than among survivors with severe
disease, p < 0.00065 (Wilcoxon); and higher in severe disease than among those with uncomplicated malaria, p < 1.27 × 10
-12 (Wilcoxon).
Horizontal line is the median, brackets span the 25
th to 75
th percentile.
Figure 2 Monocyte ICAM-1 mean fluorescence intensity (MFI) among patients with increasing severity of malaria. Higher values were
observed among subjects with uncomplicated malaria, p = 0.007 (Kruskal-Wallis). Values were not statistically different between survivors with
severe disease and fatal cases, p = 0.79 (Wilcoxon). Patients with uncomplicated malaria had significantly higher values than either severe malaria
survivors or fatal cases, p < 0.0017 (Wilcoxon). Horizontal line is the median, brackets span the 25
th to 75
th percentile. The number of patients in
each category differs from Figure 1 because some patients with sICAM-1 measures did not have monocyte ICAM-1 measurement.
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sion (monocyte MFI) among the three categories of
severity-of-illness is shown in Figure 2. Monocyte
ICAM-1 expression also followed a log-normal distribu-
tion. Median (inter-quartile range) of monocyte ICAM-1
expression among UM patients was 250 (177-345);
among SM-s patients was 165 (91-256); and among SM-
f patients was 177 (91-283). UM patients had signifi-
cantly higher monocyte ICAM levels compared with
severe or fatal cases, p = 0.007, Kruskal-Wallis test.
Cerebral malaria versus severe malaria anaemia
To compare ICAM-1 levels among children with
two major severe malaria syndromes, survivors and
non-survivors were grouped into those with cerebral
malaria only (CM) and those with severe malaria anae-
mia only (SMA). Patients with a combination of both
CM and SMA (n = 11, Table 1) were not included in
the comparison. Blood soluble ICAM-1 concentrations
were not significantly different between children with
CM (490 ng/mL; IQR 362-552) compared to those with
SMA (474 ng/mL; IQR 389-600). See Figure 3. A com-
parison of plasma ICAM-1 concentrations (rather than
blood ICAM-1 concentrations) was also not significantly
different between those with CM (645 ng/mL; IQR 478-
741) and those with SMA (528 ng/mL; IQR 448-668).
However, levels in each severe syndrome were signifi-
cantly higher than in UM patients, p < 0.0001, Kruskal-
Wallis test. See Figure 3.
In contrast, monocyte surface ICAM-1 expression dif-
fered among those with CM alone compared with SMA
alone. The results, shown in Figure 4, demonstrate sig-
nificantly lower monocyte ICAM-1 mean fluorescence
intensity among those with SMA (median MFI = 120;
IQR 80-212) compared with either CM (median MFI =
195; IQR 144-326) or UM (median MFI = 250; IQR
177-345), p < 0.0001, Kruskal-Wallis test.
The relationship between soluble and monocyte
ICAM-1 levels and patient categories is shown in Figure
5. For the overall dataset, no direct linear correlation
between soluble ICAM-1 levels and monocyte ICAM-1
expression was found, r
2 = 0.02. Correlation remained
weak even when values were fitted to non-linear models
or were log-transformed. Among patients with UM,
there was a weak positive correlation between soluble
and monocyte ICAM-1 levels, slope = 0.57, r
2 =0 . 2 7 ,
p < 0.0001. Values for patients with CM, SMA, and UM
clustered around different medians.
Discussion
ICAM-1 is a major cytoadhesion ligand for PfEMP-1,
which is expressed by parasitized erythrocytes. Previous
Figure 3 Soluble ICAM-1 in severe malaria anaemia (SMA), cerebral malaria (CM), and uncomplicated malaria (UM). Concentrations were
significantly different in three-way comparison, p < 0.0001 (Kruskal-Wallis). Values were not significantly different between cerebral malaria and
severe malaria anaemia, p = 0.776 (Wilcoxon). Values among subjects with UM were significantly lower compared to those with SMA (p < 2.9 ×
10
-12) or compared to those with CM (p < 1.83 × 10
-9, Wilcoxon). Horizontal line is the median, brackets span the 25
th to 75
th percentile.
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that ICAM-1 expression may directly contribute to
cytoadhesion of malaria infected red cells or may serve
to recruit leukocytes to sites of endothelial activation
[6,9-12]. Studies measuring soluble ICAM-1 alone have
found increased levels with greater disease severity, but
no association with specific cytoadhesive syndromes
[13,17,18,20-23]. Studies of ICAM-1 expression on cir-
culating monocytes found higher levels in acute illness
compared with convalescence [24]. Previous studies
have not measured both soluble ICAM-1 and peripheral
blood monocyte ICAM-1 expression in the same cohort
of patients. This study examined the association
between measurements of both soluble and cellular
ICAM-1 with categories of clinical severity and with
specific malaria syndromes in 160 children with docu-
mented P. falciparum infection.
Soluble ICAM-1 has been suggested by other authors
to result principally from proteolytic cleavage (shedding)
of membrane ICAM-1 expressed on endothelial cells
and monocytes [28]. In this study, plasma and whole
blood levels of soluble ICAM-1 followed a log-normal
distribution in children with malaria. Consistent with
previously published work [13,23], soluble ICAM-1
levels were found to be significantly higher among
children with severe malaria syndromes or fatal malaria
compared to those with uncomplicated malaria. These
higher soluble ICAM-1 concentrations may reflect a
combination of greater inflammatory response, increased
endothelial cell activation with ICAM-1 shedding, or
reduced soluble ICAM-1 clearance. Also consistent with
previous work [22,23], soluble ICAM-1 levels did not
distinguish patients with cerebral malaria from those
with severe malaria anaemia. This was true even when
plasma soluble ICAM-1 levels were corrected for the
degree of anaemia in each patient.
Increased ICAM-1 expression on monocytes may be
beneficial for the host with uncomplicated P. falciparum
infection. For example, ICAM-1 expression on monocytes
is required for interferon-g release by NK cells in response
to parasitized red cells [2]. In this study children with
uncomplicated malaria, treated as outpatients, had signifi-
cantly higher monocyte ICAM-1 expression than those
with severe or fatal disease. Whether the higher observed
monocyte ICAM-1 levels among outpatients were the
result of higher baseline expression, increased activation in
response to inflammatory cytokines, or reduced shedding
due to a milder clinical course could not be determined.
In contrast, high expression of ICAM-1 on cerebral
endothelial cells may contribute to cytoadhesion of
Figure 4 Monocyte ICAM-1 mean fluorescence intensity (MFI) in severe malaria anaemia (SMA), cerebral malaria (CM) and
uncomplicated malaria (UM). Monocyte ICAM-1 values were significantly different among the three groups, p < 0.0001 (Kruskal-Wallis). Values
in patients with cerebral malaria were significantly higher than those with severe malaria anaemia, p < 0.0014 (Wilcoxon). Values in patients with
cerebral malaria were not significantly different from levels observed in patients with uncomplicated malaria, p = 0.49. Horizontal line is the
median, brackets span the 25
th to 75
th percentile. The number of patients in each category differs from Figure 3 because some patients with
sICAM-1 measures did not have monocyte ICAM-1 measurement.
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Page 7 of 10parasitized red cells and cerebral malaria [11,12]. In the
subset of patients with severe disease, inflammatory cyto-
kines result in increased expression of cell-surface ICAM-
1. In contrast to those with uncomplicated infection,
ICAM-1 expression measured on circulating monocytes in
patients with severe inflammatory malaria syndromes may
reflect levels found on endothelial cells and the subset of
patients with severe a cytoadhesive syndrome such as cere-
bral malaria might be expected to have higher levels of
ICAM-1 expression compared with those with severe
malaria anaemia. In addition, among such patients with
severe disease, those with monocytes exhibiting high
ICAM-1 expression may co-localize monocytes to parasi-
tized red cells adherent to brain endothelium contributing
further to the lesion of cerebral malaria, while in contrast,
patients with low monocyte ICAM-1 may have less co-
localization and reduced risk of cerebral malaria [12]. Con-
sistent with either of these hypotheses, this study observed
that patients with cerebral malaria had significantly higher
monocyte ICAM-1 levels compared with those with severe
malaria anaemia alone.
This study had several limitations. As an observational
study, only associations may be drawn between ICAM-1
measurements and clinical outcomes. Such associations
may be confounded by factors not included in the analy-
sis. Secondly, although the study subjects were from the
same region (urban Kampala, Uganda) and studied over
a limited time frame (24 months), it is possible that dif-
ferent strains of parasites with different adhesive proper-
ties to ICAM-1 were distributed unequally among the
different clinical groups. ICAM-1 was only measured at
clinical presentation and it is not known if serial mea-
surements would lead to different conclusions. Because
monocytes are readily accessible, they are an appealing
surrogate for endothelial cell expression. However, both
regulation of ICAM-1 expression and membrane shed-
ding from proteolytic cleavage may differ for endothelial
cells and monocytes. Because the endothelium repre-
sents the largest organ in the body, direct assessment of
endothelial ICAM-1 in specific organ beds affected by
malaria may be a more important but more challenging
source to study. Finally, soluble and monocyte ICAM-1
levels in patients with asymptomatic parasitaemia or
healthy controls were not measured nor was testing
done in individuals with genetic variants of ICAM-1
[29-31].
Figure 5 Lack of correlation between blood levels of soluble ICAM-1 (y-axis) and monocyte cell-surface ICAM-1 (x-axis) in children
with malaria. Filled circles represent patients with uncomplicated malaria (n = 50), crosses represent patients with cerebral malaria (n = 33), and
triangles represent patients with severe malarial anaemia (n = 52). Ovals represent interquartile ranges of data for each group in each dimension.
Overall there is little correlation between soluble and cell-surface values. However, values cluster according to patient groups. Patients with
either cerebral malaria or severe malaria anaemia have higher soluble ICAM-1 levels compared with uncomplicated malaria. Monocyte ICAM-1
levels are higher in cerebral malaria patients compared with severe malaria anaemia patients.
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molecular pathology of malaria remains important. In
the future, proteomics technology may allow investiga-
tors to distinguish between ICAM-1 shed from the vas-
cular endothelium versus that shed from monocytes
[32,33]. The former may provide the least invasive sur-
rogate of endothelial expression relevant in cytoadhe-
sion, while the latter may reveal the proportion engaged
in an immune response. Further examination of cases
stratified by severity and by syndrome may indeed clar-
ify the predictive dualities of the physiology of ICAM-1
in malaria. In the meantime, to clarify further the role
of ICAM-1 in malaria, measurement of both cell-surface
and soluble ICAM-1 are recommended for clinical and
laboratory studies of ICAM-1 and malaria.
Additional material
Additional file 1: Blood ICAM1 (ng/mL) and Plasma ICAM1 (ng/mL)
in 160 children with P falciparum malaria. Plasma and blood
concentrations of soluble ICAM-1. Blood levels were derived from
measured plasma levels and the measured haematocrit.
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